Literature DB >> 10828306

Biological activity in vitro of side-chain modified analogues of calcitriol.

A Opolski1, J Wietrzyk, A Siwinska, E Marcinkowska, A Chrobak, C Radzikowski, A Kutner.   

Abstract

The results of our studies on the biological activity of side-chain modified analogues of vitamin D are reviewed. These analogues appeared to be effective in induction of cell differentiation, inhibition of tumour cell proliferation in vitro and in increasing of antitumour effect of cytostatics. On the other hand, inhibition of cytostatic-induced apoptosis by these compounds was observed. The mechanism of the antiproliferative effect of calcitriol analogues in vitro is discussed. The induction of antigens CD14 and CD11b expression and phagocytic activity of HL-60 cells after exposure to these compounds is related to their effect on cell differentiation. The differentiation of the HL-60 leukaemia cells induced by side-chain modified analogues of calcitriol increases their sensitivity to the antiproliferative effect of cisplatin, doxorubicin and genistein, despite of that this pretreatment causes resistance of these cells to cytostatics-induced apoptosis. We observed a synergistic antiproliferative effect of the combined therapy using analogues of calcitriol with subsequent treatment with the above-mentioned cytostatics. This effect was measured as a significant decrease of the ID50 values for each cytostatic applied after pretreatment of the tumour cells with the calcitriol analogues. The results presented suggest that the improved therapeutic effect may be achieved also in vivo by the combined application of the analogues (without calcemic activity) of calcitriol with antitumour agents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10828306     DOI: 10.2174/1381612003400407

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  7 in total

1.  Vitamin D analogs combined with 5-fluorouracil in human HT-29 colon cancer treatment.

Authors:  Magdalena Milczarek; Beata Filip-Psurska; Wiesław Swiętnicki; Andrzej Kutner; Joanna Wietrzyk
Journal:  Oncol Rep       Date:  2014-06-11       Impact factor: 3.906

2.  p53 directly activates cystatin D/CST5 to mediate mesenchymal-epithelial transition: a possible link to tumor suppression by vitamin D3.

Authors:  Sabine Hünten; Heiko Hermeking
Journal:  Oncotarget       Date:  2015-06-30

3.  Synthesis and Biological Activity of Diastereomeric and Geometric Analogs of Calcipotriol, PRI-2202 and PRI-2205, Against Human HL-60 Leukemia and MCF-7 Breast Cancer Cells.

Authors:  Magdalena Milczarek; Michał Chodyński; Beata Filip-Psurska; Agnieszka Martowicz; Małgorzata Krupa; Krzysztof Krajewski; Andrzej Kutner; Joanna Wietrzyk
Journal:  Cancers (Basel)       Date:  2013-10-31       Impact factor: 6.639

4.  Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model.

Authors:  Magdalena Milczarek; Mateusz Psurski; Andrzej Kutner; Joanna Wietrzyk
Journal:  BMC Cancer       Date:  2013-06-18       Impact factor: 4.430

5.  Antiproliferative Activity and in Vivo Toxicity of Double-Point Modified Analogs of 1,25-Dihydroxyergocalciferol.

Authors:  Justyna Trynda; Eliza Turlej; Magdalena Milczarek; Anita Pietraszek; Michał Chodyński; Andrzej Kutner; Joanna Wietrzyk
Journal:  Int J Mol Sci       Date:  2015-10-20       Impact factor: 5.923

6.  Vitamin D Analogs Potentiate the Antitumor Effect of Imatinib Mesylate in a Human A549 Lung Tumor Model.

Authors:  Ewa Maj; Beata Filip-Psurska; Marta Świtalska; Andrzej Kutner; Joanna Wietrzyk
Journal:  Int J Mol Sci       Date:  2015-11-13       Impact factor: 5.923

7.  Unfavorable effect of calcitriol and its low-calcemic analogs on metastasis of 4T1 mouse mammary gland cancer.

Authors:  Artur Anisiewicz; Agata Pawlik; Beata Filip-Psurska; Eliza Turlej; Stanisław Dzimira; Magdalena Milczarek; Katarzyna Gdesz; Diana Papiernik; Joanna Jarosz; Dagmara Kłopotowska; Andrzej Kutner; Andrzej Mazur; Joanna Wietrzyk
Journal:  Int J Oncol       Date:  2017-11-02       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.